Document Detail

Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients.
MedLine Citation:
PMID:  18258763     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Frequent negative consequence of chemotherapy (CHT) is ovarian damage and premature ovarian failure (POF). Aim of this prospective case-control study is evaluation of GnRH analogue (GnRH-a) administration to patients with Hodgkin lymphoma (HL) during CHT and prevention of ovarian damage depending upon CHT regimen. METHODS: Study group consists of 72 patients in fertile age (18-35 years) with HL diagnosis treated in 2004-2005 by curative CHT together with GnRH analogue (Triptorelin) administration according to a standardized protocol. Patients were divided into three groups according to the stage of disease and treated by three types of CHT regimens (A,B,C) with increased cytotoxicity. Ovarian function of all patients was assessed by gonadotrophin levels (FSH, LH) analysis from peripheral blood before treatment and also 6 and 12 month after it. The number of women with POF after CHT in study group was compared with control group (n = 45, age 18-35 years) of patients treated in 2002-2003 according to the same protocol but without protective GnRH analogue application. RESULTS: In study group with GnRH analogue administration during CHT, there was significantly (P < 0.001) fewer cases with POF 6 and 12 month after the end of CHT (37.5% and 20.8%, respectively) than in control group (73.3% and 71.1%, respectively). Comparative analysis depending on cytotoxicity of CHT regimen used showed significant differences in percentage of patient with acquired POF between study and control group only in less aggressive CHT protocols. CONCLUSIONS: Study showed a significant reduction of ovarian failure risk in women with HL treated with less aggressive CHT regimens plus a GnRH analogue.
M Huser; I Crha; P Ventruba; R Hudecek; J Zakova; L Smardova; Z Kral; J Jarkovsky
Related Documents :
740583 - Clinical considerations in the management of the menopause: the endometrium.
19171333 - Does endometrial integrin expression in endometriosis patients predict enhanced in vitr...
24011463 - Intraoperative efficiency of fluorescence imaging by visually enhanced lesion scope (ve...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-02-07
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  23     ISSN:  1460-2350     ISO Abbreviation:  Hum. Reprod.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-19     Completed Date:  2008-05-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  England    
Other Details:
Languages:  eng     Pagination:  863-8     Citation Subset:  IM    
Department of Obstetrics and Gynecology, Brno University Hospital and Masaryk University School of Medicine, Brno, Czech Republic.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Case-Control Studies
Drug Therapy
Follicle Stimulating Hormone / blood
Hodgkin Disease / drug therapy*
Luteinizing Hormone / blood
Luteolytic Agents / administration & dosage*
Ovarian Failure, Premature / chemically induced*,  drug therapy*,  prevention & control
Ovary / drug effects*
Treatment Outcome
Triptorelin / administration & dosage*
Reg. No./Substance:
0/Luteolytic Agents; 57773-63-4/Triptorelin; 9002-67-9/Luteinizing Hormone; 9002-68-0/Follicle Stimulating Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Photoperiodic regulation of behavioral responses to bacterial and viral mimetics: a test of the wint...
Next Document:  Aberrant expression of angiopoietins-1 and -2 and vascular endothelial growth factor-A in peri-impla...